Plain-English fact sheet
Semaglutide
Also known as Ozempic, Wegovy, Rybelsus
Semaglutide is a GLP-1 receptor agonist with strong human evidence for specific FDA-approved uses, but each brand and formulation has its own label.
Quick answer
Semaglutide is the active ingredient in several FDA-approved prescription medicines. Approval is product- and use-specific; it does not make every semaglutide product or every claimed use approved.
By the PeptideFactSheets Editorial Team. Claims are source-checked under our editorial policy; clinician review is identified only when a named reviewer is shown.
What is Semaglutide?
Semaglutide is a manufactured peptide-like medicine that acts on the GLP-1 receptor, part of a signaling system involved in blood sugar, appetite, and digestion.
The active ingredient appears in different prescription products. Those products are not interchangeable in every context, and their FDA labels differ.
Why are people interested in it?
People commonly search for semaglutide because of its established roles in type 2 diabetes care and chronic weight management.
Researchers also study cardiovascular, kidney, liver, and other outcomes. A study result does not automatically create a new approved use.
Current regulatory status
FDA-approved semaglutide products include products for type 2 diabetes and products for chronic weight management in eligible patients. Some labels include cardiovascular risk-reduction indications. Check the current label for the exact product and use.
What is it approved for?
- Improving blood sugar control in specified people with type 2 diabetes
- Chronic weight management in specified people with obesity or overweight
- Reducing specified cardiovascular risks in certain labeled populations
What is it being studied for?
Investigational areas
- Additional kidney, liver, cardiovascular, and neurobehavioral outcomes
- Uses outside the population or indication of a particular FDA-approved label
Evidence snapshot
Multiple large randomized trials support approved uses. Evidence for a specific goal must still be matched to the product, population, outcome, and current label.
Potential benefits being researched
- Randomized trials show clinically meaningful benefits for the uses and populations described in approved labels.
- Ongoing studies are asking whether benefits extend to additional conditions; those questions should remain separate from established indications.
Potential does not mean proven. Study design, population, endpoint, and regulatory review matter.
Known or possible risks
- Common gastrointestinal effects can include nausea, vomiting, diarrhea, constipation, and abdominal discomfort.
- Current labels contain important warnings and contraindications, including a boxed warning about thyroid C-cell tumors observed in rodents.
- Other labeled concerns can include pancreatitis, gallbladder disease, kidney injury related to dehydration, and low blood sugar when combined with certain diabetes medicines.
- Compounded products are not FDA-approved and do not undergo the same premarket review for safety, effectiveness, and quality.
What we still do not know
- How every benefit-risk tradeoff changes across individual medical histories
- Whether ongoing trials will support additional labeled indications
- Very long-term outcomes for newer uses and broader populations
- The safety, quality, and equivalence of unapproved products marketed as semaglutide
Plain-English takeaway
Semaglutide has substantial human evidence and legitimate approved uses. The careful question is not simply whether semaglutide is approved, but which product, for whom, and for what exact use.
Research and reference links
Use these primary and reputable sources to verify status and read beyond this summary. Trial registries may list studies without proving a benefit.
- 1FDA Drugs@FDA search: semaglutide
Official FDA approval records, labels, and regulatory history.
- 2FDA: Wegovy cardiovascular risk-reduction approval
FDA announcement describing the approved indication and supporting evidence.
- 3ClinicalTrials.gov studies: semaglutide
Current and completed registered clinical studies.
- 4PubMed research: semaglutide randomized trial
Peer-reviewed literature indexed by the National Library of Medicine.